Trial Profile
A Treatment Protocol to Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Expanded access
- Sponsors Genentech; InterMune
- 24 May 2017 Pooled long-term results from two real-world studies (NCT02699879 and NCT02141087) presented at the Digestive Disease Week 2017
- 24 May 2017 Safety findings from pooled trial databases (NCT00662038, NCT02699879 and NCT02141087); resultpresented at the 113th International Conference of the American Thoracic Society
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society